• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

持续激活的细胞外信号调节激酶使癌细胞对多柔比星敏感:p53-表皮生长因子受体-细胞外信号调节激酶信号通路的作用

Constitutively activated ERK sensitizes cancer cells to doxorubicin: Involvement of p53-EGFR-ERK pathway.

作者信息

Kumari Ratna, Chouhan Surbhi, Singh Snahlata, Chhipa Rishi Raj, Ajay Amrendra Kumar, Bhat Manoj Kumar

机构信息

National Centre for Cell Science, Savitribai Phule Pune University Campus, Ganeshkhind, Pune 411 007, India.

出版信息

J Biosci. 2017 Mar;42(1):31-41. doi: 10.1007/s12038-017-9667-8.

DOI:10.1007/s12038-017-9667-8
PMID:28229963
Abstract

The tumour suppressor gene p53 is mutated in approximately 50% of the human cancers. p53 is involved in genotoxic stress-induced cellular responses. The role of EGFR and ERK in DNA-damage-induced apoptosis is well known. We investigated the involvement of activation of ERK signalling as a consequence of non-functional p53, in sensitivity of cells to doxorubicin. We performed cell survival assays in cancer cell lines with varying p53 status: MCF-7 (wild-type p53, WTp53), MDA MB-468 (mutant p53, MUTp53), H1299 (absence of p53, NULLp53) and an isogenic cell line MCF-7As (WTp53 abrogated). Our results indicate that enhanced chemosensitivity of cells lacking wild-type p53 function is because of elevated levels of EGFR which activates ERK. Additionally, we noted that independent of p53 status, pERK contributes to doxorubicin-induced cell death.

摘要

肿瘤抑制基因p53在大约50%的人类癌症中发生突变。p53参与基因毒性应激诱导的细胞反应。表皮生长因子受体(EGFR)和细胞外信号调节激酶(ERK)在DNA损伤诱导的细胞凋亡中的作用已为人所知。我们研究了由于p53功能缺失导致的ERK信号激活在细胞对多柔比星敏感性中的作用。我们在具有不同p53状态的癌细胞系中进行了细胞存活分析:MCF-7(野生型p53,WTp53)、MDA MB-468(突变型p53,MUTp53)、H1299(无p53,NULLp53)以及同基因细胞系MCF-7As(野生型p53缺失)。我们的结果表明,缺乏野生型p53功能的细胞化疗敏感性增强是由于激活ERK的EGFR水平升高所致。此外,我们注意到,与p53状态无关,磷酸化ERK(pERK)会导致多柔比星诱导的细胞死亡。

相似文献

1
Constitutively activated ERK sensitizes cancer cells to doxorubicin: Involvement of p53-EGFR-ERK pathway.持续激活的细胞外信号调节激酶使癌细胞对多柔比星敏感:p53-表皮生长因子受体-细胞外信号调节激酶信号通路的作用
J Biosci. 2017 Mar;42(1):31-41. doi: 10.1007/s12038-017-9667-8.
2
Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.RAF/MEK/ERK和PI3K/PTEN/AKT信号通路在恶性转化和耐药中的作用。
Adv Enzyme Regul. 2006;46:249-79. doi: 10.1016/j.advenzreg.2006.01.004. Epub 2006 Jul 18.
3
Allele-specific silencing of mutant p53 attenuates dominant-negative and gain-of-function activities.突变型p53的等位基因特异性沉默可减弱显性负性和功能获得性活性。
Oncotarget. 2016 Feb 2;7(5):5401-15. doi: 10.18632/oncotarget.6634.
4
Reactivating p53 and Inducing Tumor Apoptosis (RITA) Enhances the Response of RITA-Sensitive Colorectal Cancer Cells to Chemotherapeutic Agents 5-Fluorouracil and Oxaliplatin.重新激活p53并诱导肿瘤凋亡(RITA)增强RITA敏感型结肠癌细胞对化疗药物5-氟尿嘧啶和奥沙利铂的反应。
Neoplasia. 2017 Apr;19(4):301-309. doi: 10.1016/j.neo.2017.01.007. Epub 2017 Mar 9.
5
Doxorubicin-induced apoptosis and chemosensitivity in hepatoma cell lines.阿霉素诱导肝癌细胞系凋亡及化疗敏感性
Cancer Chemother Pharmacol. 2002 Jan;49(1):78-86. doi: 10.1007/s00280-001-0376-4.
6
Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.抗表皮生长因子受体(EGFR)抗体西妥昔单抗与DNA交联剂顺铂在吉非替尼耐药的MDA-MB-468细胞中的生长及分子相互作用:三阴性/基底样乳腺癌治疗的新前景
Int J Oncol. 2008 Dec;33(6):1165-76.
7
Nuclear factor erythroid 2 (NF-E2) p45-related factor 2 interferes with homeodomain-interacting protein kinase 2/p53 activity to impair solid tumors chemosensitivity.核因子红细胞 2(NF-E2)p45 相关因子 2 干扰同源结构域相互作用蛋白激酶 2/p53 活性,损害实体瘤的化疗敏感性。
IUBMB Life. 2020 Aug;72(8):1634-1639. doi: 10.1002/iub.2334. Epub 2020 Jun 27.
8
The dual role of mutant p53 protein in chemosensitivity of human cancers.突变型p53蛋白在人类癌症化疗敏感性中的双重作用。
Anticancer Res. 1996 Nov-Dec;16(6B):3845-8.
9
Phosphorylated Hsp27 activates ATM-dependent p53 signaling and mediates the resistance of MCF-7 cells to doxorubicin-induced apoptosis.磷酸化热休克蛋白 27 激活 ATM 依赖性 p53 信号通路并介导 MCF-7 细胞对阿霉素诱导的细胞凋亡的抵抗。
Cell Signal. 2013 May;25(5):1176-85. doi: 10.1016/j.cellsig.2013.01.017. Epub 2013 Jan 26.
10
Strategy to enhance efficacy of doxorubicin in solid tumor cells by methyl-β-cyclodextrin: Involvement of p53 and Fas receptor ligand complex.通过甲基-β-环糊精提高阿霉素在实体瘤细胞中疗效的策略:p53和Fas受体配体复合物的作用
Sci Rep. 2015 Jul 7;5:11853. doi: 10.1038/srep11853.

引用本文的文献

1
Molecular Sentinels: Unveiling the Role of Sirtuins in Prostate Cancer Progression.分子哨兵:揭示沉默调节蛋白在前列腺癌进展中的作用
Int J Mol Sci. 2024 Dec 28;26(1):183. doi: 10.3390/ijms26010183.
2
Sirtuins as Key Regulators in Pancreatic Cancer: Insights into Signaling Mechanisms and Therapeutic Implications.沉默调节蛋白作为胰腺癌的关键调节因子:对信号传导机制及治疗意义的见解
Cancers (Basel). 2024 Dec 6;16(23):4095. doi: 10.3390/cancers16234095.
3
RBP7 functions as a tumor suppressor in HR + breast cancer by inhibiting the AKT/SREBP1 pathway and reducing fatty acid.

本文引用的文献

1
Economic downturns, universal health coverage, and cancer mortality in high-income and middle-income countries, 1990-2010: a longitudinal analysis.经济衰退、全民健康覆盖与高收入和中等收入国家的癌症死亡率(1990-2010 年):纵向分析。
Lancet. 2016 Aug 13;388(10045):684-95. doi: 10.1016/S0140-6736(16)00577-8. Epub 2016 May 25.
2
p53 status identifies triple-negative breast cancer patients who do not respond to adjuvant chemotherapy.p53状态可识别出对辅助化疗无反应的三阴性乳腺癌患者。
Breast. 2015 Jun;24(3):294-7. doi: 10.1016/j.breast.2015.01.007. Epub 2015 Feb 16.
3
Epidermal growth factor receptor signalling in human breast cancer cells operates parallel to estrogen receptor α signalling and results in tamoxifen insensitive proliferation.
视黄醇结合蛋白7(RBP7)通过抑制AKT/固醇调节元件结合蛋白1(SREBP1)信号通路并减少脂肪酸,在激素受体阳性(HR+)乳腺癌中发挥肿瘤抑制作用。
Cancer Cell Int. 2024 Mar 29;24(1):118. doi: 10.1186/s12935-024-03299-0.
4
LncRNA RASAL2-AS1 promotes METTL14-mediated m6A methylation in the proliferation and progression of head and neck squamous cell carcinoma.长链非编码RNA RASAL2-AS1在头颈部鳞状细胞癌的增殖和进展中促进METTL14介导的m6A甲基化。
Cancer Cell Int. 2024 Mar 25;24(1):113. doi: 10.1186/s12935-024-03302-8.
5
TEP SNORD12B, SNORA63, and SNORD14E as novel biomarkers for hepatitis B virus-related hepatocellular carcinoma (HBV-related HCC).TEP SNORD12B、SNORA63和SNORD14E作为乙型肝炎病毒相关肝细胞癌(HBV相关HCC)的新型生物标志物。
Cancer Cell Int. 2024 Jan 2;24(1):3. doi: 10.1186/s12935-023-03179-z.
6
Triple negative breast cancer: approved treatment options and their mechanisms of action.三阴性乳腺癌:已批准的治疗选择及其作用机制。
J Cancer Res Clin Oncol. 2023 Jul;149(7):3701-3719. doi: 10.1007/s00432-022-04189-6. Epub 2022 Aug 17.
7
TNK2/ACK1-mediated phosphorylation of ATP5F1A (ATP synthase F1 subunit alpha) selectively augments survival of prostate cancer while engendering mitochondrial vulnerability.TNK2/ACK1 介导的 ATP5F1A(ATP 合酶 F1 亚基 alpha)磷酸化选择性增强前列腺癌的存活能力,同时使线粒体易损。
Autophagy. 2023 Mar;19(3):1000-1025. doi: 10.1080/15548627.2022.2103961. Epub 2022 Jul 27.
8
Piperlongumine as a Neuro-Protectant in Chemotherapy Induced Cognitive Impairment.千里光碱作为化疗诱导认知障碍的神经保护剂。
Int J Mol Sci. 2022 Feb 11;23(4):2008. doi: 10.3390/ijms23042008.
9
ERK: A Double-Edged Sword in Cancer. ERK-Dependent Apoptosis as a Potential Therapeutic Strategy for Cancer.ERK:癌症的双刃剑。ERK 依赖性细胞凋亡作为癌症潜在的治疗策略。
Cells. 2021 Sep 22;10(10):2509. doi: 10.3390/cells10102509.
10
Cisplatin effect on head and neck squamous cell carcinoma cells is modulated by ERK1/2 protein kinases.顺铂对头颈部鳞状细胞癌细胞的作用受ERK1/2蛋白激酶调控。
Exp Ther Med. 2019 Dec;18(6):5041-5051. doi: 10.3892/etm.2019.8139. Epub 2019 Oct 25.
人乳腺癌细胞中的表皮生长因子受体信号传导与雌激素受体α信号传导平行发挥作用,并导致对他莫昔芬不敏感的增殖。
BMC Cancer. 2014 Apr 23;14:283. doi: 10.1186/1471-2407-14-283.
4
Mutant p53 in cancer: new functions and therapeutic opportunities.癌症中突变型 p53:新功能与治疗机会。
Cancer Cell. 2014 Mar 17;25(3):304-17. doi: 10.1016/j.ccr.2014.01.021.
5
The p53 target gene desmocollin 3 acts as a novel tumor suppressor through inhibiting EGFR/ERK pathway in human lung cancer.p53 靶基因桥粒芯胶蛋白 3 通过抑制人肺癌中的 EGFR/ERK 通路发挥新型肿瘤抑制作用。
Carcinogenesis. 2012 Dec;33(12):2326-33. doi: 10.1093/carcin/bgs273. Epub 2012 Aug 31.
6
Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial.TP53 基因突变对接受蒽环类或蒽环类/紫杉类辅助治疗的淋巴结阳性乳腺癌患者的预后和预测价值:来自 BIG 02-98 期 III 临床试验的结果。
Breast Cancer Res. 2012 May 2;14(3):R70. doi: 10.1186/bcr3179.
7
Extracellular signal-regulated kinases modulate DNA damage response - a contributing factor to using MEK inhibitors in cancer therapy.细胞外信号调节激酶调节 DNA 损伤反应——这是在癌症治疗中使用 MEK 抑制剂的一个促成因素。
Curr Med Chem. 2011;18(35):5476-82. doi: 10.2174/092986711798194388.
8
p53 modulates acquired resistance to EGFR inhibitors and radiation.p53 调节获得性对表皮生长因子受体抑制剂和辐射的抵抗。
Cancer Res. 2011 Nov 15;71(22):7071-9. doi: 10.1158/0008-5472.CAN-11-0128. Epub 2011 Nov 8.
9
Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities.增加来那度胺剂量治疗伴有 5 号染色体异常的高危骨髓增生异常综合征和急性髓系白血病的临床疗效。
Haematologica. 2011 Jul;96(7):963-71. doi: 10.3324/haematol.2010.039669.
10
Correlation of cellular immunity with human papillomavirus 16 status and outcome in patients with advanced oropharyngeal cancer.晚期口咽癌患者细胞免疫与人乳头瘤病毒16型状态及预后的相关性
Arch Otolaryngol Head Neck Surg. 2010 Dec;136(12):1267-73. doi: 10.1001/archoto.2010.211.